J. Pablo Abonia, MD is an Associate Professor of Pediatrics at Cincinnati Children's Hospital Medical Center (CCHMC) within the University of Cincinnati College of Medicine. His graduate research was at Roswell Park Cancer Institute and was focused upon the biology and genetics of the renin-angiotensin system (RAS).
His training in Allergy and Immunology occurred at Brigham and Women's hospital and his research work there principally focused upon the chemokine and integrins pathways that regulate the basal homing and inflammatory recruitment of mast cell progenitors to the lungs and small intestine.
In the Cincinnati Center for Eosinophilic Disorders (CCED), Dr. Abonia is focused upon eosinophils and mast cells and their role in disease such as eosinophilic esophagitis (EoE) and primary mast cell diseases. Dr Abonia currently conducts translational research, and is investigator for NIH, PCORI, and industry-sponsored multicenter clinical trials for the treatment of EoE. He supervises the research registries for eosinophilic gastrointestinal disorders, he is directly involved in the continuing development of patient databanks and bioinformatic approaches at CCHMC. The utilization and intermingling of these clinical and research resources has allowed for deep phenotypic analyses that have helped to identify and define new EoE subtypes, such as the subtype related to connective tissue disorders (CTDs, e.g., Ehlers-Danlos and Marfan's' syndromes).
Dr. Abonia is a member of the NIH supported Consortium of Eosinophilic Gastrointestinal Researchers whose primary goals are to facilitate research and extend education regarding EoE, eosinophilic gastritis, and eosinophilic colitis nationwide. As a co-investigator in CEGIR, he is the lead PI on an innovative pilot project evaluating the utility of losartan in EoE therapy.